000			01594na a2200241 4500
003			H12O
005			20180417112750.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_9539 _aRuilope Urioste, Luis Miguel _eNefrología
100			_aSegura de la Morena, Julián _91486 _eNefrología
245	0	0	_aDual-acting angiotensin receptor-neprilysin inhibition _h[artículo]
260			_bCurrent Hypertension Reports, _c2011
300			_a13(1):74-78.
500			_aFormato Vancouver: Segura J, Ruilope LM. Dual-acting angiotensin receptor-neprilysin inhibition. Curr Hypertens Rep. 2011 Feb;13(1):74-8.
501			_aPMID: 21046489
504			_aContiene 29 referencias.
520			_aLowering blood pressure by pharmacologic intervention reduces the incidence of cardiovascular events. Nevertheless, despite the widespread availability of effective antihypertensive medications, the vast majority of hypertensive patients worldwide continue to have inadequate blood pressure control. The development of new antihypertensive drugs could contribute to improving the hypertension control rate, and the blockade of new pathophysiologic pathways involved in blood pressure regulation would offer additional benefits. The dual inhibition of the angiotensin II receptor and neprilysin could provide clinical benefits in a range of cardiovascular diseases, including hypertension and heart failure.
710			_986 _aServicio de Nefrología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc979.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c979 _d979